Saturday, June 09, 2007
statins cash
juli 2004
Hooked On The Cash From Cholesterol
Statins are massive moneyspinners. But can Big Pharma sidestep expiring patents?
There's no overstating the importance of cholesterol-lowering drugs to the pharmaceutical industry. They bring in $20 billion a year in sales, the single biggest market in the $492 billion global prescription-drug business. Sales are growing at a healthy 15% clip. And with the government releasing new recommendations on July 12 encouraging doctors to drop targets for LDL -- or so-called bad cholesterol -- even lower for patients at high risk for heart attacks, sales are likely to shoot ahead even faster.
Hooked On The Cash From Cholesterol
Statins are massive moneyspinners. But can Big Pharma sidestep expiring patents?
There's no overstating the importance of cholesterol-lowering drugs to the pharmaceutical industry. They bring in $20 billion a year in sales, the single biggest market in the $492 billion global prescription-drug business. Sales are growing at a healthy 15% clip. And with the government releasing new recommendations on July 12 encouraging doctors to drop targets for LDL -- or so-called bad cholesterol -- even lower for patients at high risk for heart attacks, sales are likely to shoot ahead even faster.
# posted by roodbont @ 2:40 PM 
